# A Study of GC101 TIL in Advanced Melanoma

> **NCT06703398** · PHASE2 · RECRUITING · sponsor: **Shanghai Juncell Therapeutics** · enrollment: 98 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** GC101 TIL
- **DRUG:** dacarbazine, temozolomide, paclitaxel ,platinum or cisplatin

## Key facts

- **NCT ID:** NCT06703398
- **Lead sponsor:** Shanghai Juncell Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-20
- **Primary completion:** 2026-07-10
- **Final completion:** 2026-12-20
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06703398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06703398, "A Study of GC101 TIL in Advanced Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06703398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*